OncoMatch/Clinical Trials/NCT06295432
A Phase II Clinical Trial of DZD9008 in Combination With AZD4205 in Standard Treatment Failed NSCLC Patients With EGFR Mutations (WU-KONG21)
Is NCT06295432 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies DZD9008+AZD4205 for non-small cell lung cancer.
Treatment: DZD9008+AZD4205 — DZD9008 in combination with AZD4205 for the treatment of patients with advanced NSCLC with EGFR mutations who have progressed after standard treatment. The purpose of this study is to assess the safety and efficacy of this combination therapy.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Small Cell Lung Carcinoma
Biomarker criteria
Required: EGFR any mutation
Required: EGFR sensitizing mutation
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: standard systemic therapy — metastatic/locally advanced
Subjects should have progressed on, or be intolerant of prior standard systemic therapy for metastatic/locally advanced disease.
Cannot have received: onco-immunotherapy (PD-1)
Prior treatment with any onco-immunotherapy (e.g. PD-1) within 4 weeks before the first administration of IP.
Cannot have received: cytotoxic chemotherapy
Any cytotoxic chemotherapy, or other anticancer drugs from a previous treatment regimen within 2 weeks before the first administration of IP.
Cannot have received: radiation therapy
Radiotherapy within 2 weeks of the first dose or have not recovered from radiotherapy-related toxicity.
Cannot have received: investigational drug
Treatment with any investigational drug (or unable to stop using) within 4 weeks before the first administration of IP.
Lab requirements
Blood counts
ANC ≥ 1.5 x 10^9/L; Absolute lymphocyte count ≥ 0.8 x 10^9/L; Platelets ≥ 100 x 10^9/L; Hemoglobin ≥ 9 g/dL
Kidney function
Creatinine ≤ 1.5 x ULN, or measured creatinine clearance ≥ 50 mL/min (Cockcroft-Gault)
Liver function
Total bilirubin ≤ 1.5 x ULN if no liver metastases or ≤ 3 x ULN in the presence of documented Gilbert's Syndrome or liver metastases; ALT and AST ≤ 2.5 x ULN if no liver involvement or ≤ 5 x ULN with liver involvement
Cardiac function
INR ≤ 1.5 x ULN and APTT ≤ 1.5 x ULN; QTc ≤ 470 msec; LVEF ≥ 55% by ECHO
Adequate organ system functions, as outlined below...
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify